NCT07143513Completed
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
The primary objective of this study is to characterize the safety profile of sotorasib.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 102 (actual)
- First submitted
- 20 Aug 2025
- Start date
- 11 Aug 2025
- Primary completion date
- 7 Dec 2025
- Lead sponsor
- Amgen
- Diseases
- Lung cancer
- NCT number
- NCT07143513
What you commit to
- Study type: Observational
- Participants enrolled: 102
- From 11 Aug 2025 to the primary completion date, 7 Dec 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Documentation of being a non-Chinese ethnicity.
Who the study is looking for
- Adult (≥ 18 years) as of the index date.
- KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
- Received at least 1 dose of sotorasib.
- Receipt of at least 1 prior systemic therapy before use of sotorasib.
- Obtained ICF, if required.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Boao Evergrande International Hospital Coordinator of this site? Confirm its status | Qionghai | China | Unknown status |
| Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital) Coordinator of this site? Confirm its status | Qionghai | China | Unknown status |
| Boao Super Hospital Coordinator of this site? Confirm its status | Qionghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.